CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model
- 1 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 85 (6), 1177-1182
- https://doi.org/10.1007/s00280-020-04077-1
Abstract
Glioblastoma is the most devastating primary brain tumor and effective therapies are not available. Treatment is based on surgery followed by radio and chemotherapy with temozolomide (TMZ), but TMZ increases patient survival only by 2 months. CD73, an enzyme responsible for adenosine production, emerges as a target for glioblastoma treatment. Indeed, adenosine causes tumor-promoting actions and CD73 inhibition increases sensitivity to TMZ in vitro. Here, a cationic nanoemulsion to nasal delivery of siRNA CD73 (NE-siRNA CD73) aiming glioblastoma treatment was employed alone or in combination with TMZ. In vitro, two glioblastoma cell lines (C6 and U138MG) with a chemo-resistant profile were used. Treatment alone with NE-siRNA CD73 reduced C6 and U138MG glioma cell viability by 70% and 25%, respectively. On the other hand, when NE-siRNA + TMZ combined treatment was employed, a reduction of 85% and 33% of cell viability was observed. Notably, treatment with NE-siRNA CD73 of glioma-bearing Wistar rats reduced tumor size by 80%, 60% more than the standard chemotherapy with TMZ, but no synergistic or additive effect was observed in vivo. Additionally, NE-siRNA CD73, TMZ or combined therapy decreased adenosine levels in liquor confirming the importance of this nucleoside on in vivo GB growth. Finally, no hemolytic potential was observed. These results suggest that nasal administration of NE-siRNA CD73 exhibits higher antiglioma effect when compared to TMZ. However, no synergistic or additive in vivo was promoted by the therapeutic regimen employed in this study.Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (422298/2016-6)
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (16/2551-0000265-7)
This publication has 14 references indexed in Scilit:
- Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical ApproachMolecular Neurobiology, 2019
- CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma GrowthMolecular Neurobiology, 2019
- Evidence-Based Practice: Temozolomide Beyond GlioblastomaCurrent Oncology Reports, 2019
- Obstacles to Brain Tumor Therapy: Key ABC TransportersInternational Journal of Molecular Sciences, 2017
- Enhanced photostability, radical scavenging and antitumor activity of indole-3-carbinol-loaded rose hip oil nanocapsulesMaterials Science and Engineering: C, 2017
- The epidemiology of glioma in adults: a "state of the science" reviewNeuro-Oncology, 2014
- Ketoprofen-loaded polymeric nanocapsules selectively inhibit cancer cell growth in vitro and in preclinical model of glioblastoma multiformeInvestigational New Drugs, 2013
- 5′‐ectonucleotidase mediates multiple‐drug resistance in glioblastoma multiforme cellsJournal of Cellular Physiology, 2012
- The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferationMolecular and Cellular Biochemistry, 2008
- Optimal role of temozolomide in the treatment of malignant gliomasCurrent Neurology and Neuroscience Reports, 2005